Evidence map›Paper›PMID 30701023›Full record

ArticleOncotarget2018

A comparison of prostate cancer bone metastases on

Stephanie A Harmon, Esther Mena, Joanna H Shih, Stephen Adler, Yolanda McKinney, Ethan Bergvall, Sherif Mehralivand, Adam G Sowalsky, Anna Couvillon, Ravi A Madan and 8 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Whole-Body [Tomography (Ann Arbor, Mich.) · 2021
    Trial
  2. Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024
    Observational
  3. Tracing prostate cancer - the evolution of PET-CT applications.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2024
    Review
  4. With New Technology Comes Great Responsibility: Prostate-Specific Membrane Antigen Imaging in Recurrent Prostate Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Understanding and ImprovingProstate cancer · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Stephanie A HarmonClinical Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD, USA.
Esther MenaMolecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA.
Joanna H ShihBiometric Research Branch, National Cancer Institute, NIH, Bethesda, MD, USA.
Stephen AdlerClinical Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD, USA.
Yolanda McKinneyMolecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA.
Ethan BergvallMolecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA.
Sherif MehralivandMolecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA.
Adam G SowalskyLaboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Anna CouvillonGenitourinary Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD, USA.
Ravi A MadanGenitourinary Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD, USA.
James L GulleyGenitourinary Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD, USA.
Janet EaryCancer Imaging Program, National Cancer Institute, NIH, Rockville, MD, USA.
Ronnie C MeaseRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Martin G PomperRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
William L DahutGenitourinary Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD, USA.
Baris TurkbeyMolecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA.
Liza LindenbergMolecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA.
Peter L ChoykeMolecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA.
National Cancer Institute · USJohns Hopkins University · USCenter for Cancer Research · USFrederick National Laboratory for Cancer Research · US

Funding

Prostate Cancer ImagingZIABC010655 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2009 to 2025
$49.2M
Training/Dissemination-Resource for Molecular Imaging Agents in Precision MedicineP41EB024495 · NIBIB · UT SOUTHWESTERN MEDICAL CENTER · PI MARTIN G POMPER · 2017 to 2026
$11.8M
PSMA-based Cancer Imaging AgentsR01CA134675 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI POMPER, MARTIN G · 2009 to 2025
$6.2M
PSMA Directed Imaging of Prostate Cancer Focus on Androgen Receptor DynamicsU01CA183031 · NCI · JOHNS HOPKINS UNIVERSITY · PI DEWEESE, THEODORE L, POMPER, MARTIN G · 2015 to 2017
$1.2M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENCI NIH HHS R01 CA134675NCI NIH HHS U01 CA183031NIBIB NIH HHS P41 EB024495
6 · The paper itself

Abstract

purposeProstate-Specific Membrane Antigen (PSMA) PET/CT has been introduced as a sensitive method for characterizing metastatic prostate cancer. The purpose of this study is to compare the spatial concordance of

methodsProstate cancer patients with known bone metastases underwent PSMA-targeted PET/CT (

resultsThe study included 149 lesions in 19 patients. Qualitatively, lesions exhibited a heterogeneous range of spatial concordance between PSMA and NaF uptake from completely matched to completely discordant. Quantitatively, overlap volume decreased as a function of tracer intensity. and disease status, where lesions from patients with castration-sensitive disease showed higher spatial concordance while lesions from patients with castration-resistant disease demonstrated more frequent spatial discordance.

conclusionAs metastatic prostate cancer progresses from castration-sensitive to castration-resistant, greater discordance is observed between NaF PET and PSMA PET uptake. This may indicate a possible phenotypic shift to tumor growth that is more independent of bone remodeling via osteoblastic formation.

Indexed as

bone metastasesprostate cancerprostate specific membrane antigensodium fluoridespatial analysis

Identifiers

PMID30701023
PMCPMC6340866
OpenAlexW2907580697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.